Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease

As the societal and economic burdens of Alzheimer's disease (AD) continue to mount, so does the need for therapies that slow the progression of the illness. Beta amyloid has long been recognized as the pathologic hallmark of AD, and the past decade has seen significant progress in the development of various immunotherapeutic approaches targeting beta amyloid. This paper reviews active and passive approaches aimed at beta amyloid, with a focus on clinical trial data.

• Publication year

  2012

• Venue

  International Journal of Alzheimer's Disease

• Publication date

  2012-01-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1155/2012/628070PMID 22292124PMCID 3265072
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The worldwide economic impact of dementia 2010

  2013cited by this paper
• Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration

  2011cited by this paper
• P2‐461: The Aβ peptide conjugate vaccine, acc‐001, generates n‐terminal anti‐ Aβ antibodies in the absence of Aβ directed t‐cell responses

  2011cited by this paper
• Amyloid‐related imaging abnormalities in amyloid‐modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup

  2011cited by this paper
• Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease

  2010cited by this paper
• P1‐455: Effects of memantine on global clinical status in patients with moderate Alzheimer's: Results of a 12‐week, randomized, placebo‐controlled trial

  2010cited by this paper
• P1‐440: Pharmacokinetics of ponezumab (PF‐04360365) following a single‐dose intravenous infusion in Japanese patients with mild‐to‐moderate Alzheimer's disease: Preliminary results

  2010cited by this paper
• O3‐05‐01: Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer's disease

  2010cited by this paper
• A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE

  2010influential reference
• P3‐309: Pyroglutamate modified Abeta accumulates around synapses and micro‐plaques early in the development of Alzheimer's disease

  2010cited by this paper
• P1‐448: Solanezumab was safe and well‐tolerated for Asian patients with mild‐to‐moderate Alzheimer's disease in a multicenter, randomized, open‐label, multi‐dose study

  2010cited by this paper
• Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology.

  2010cited by this paper
• P1‐457: Safety, tolerability, and preliminary efficacy of SAM‐531, a 5HT‐6 antagonist, in subjects with mild‐to‐moderate Alzheimer's disease: Results from a phase 2a study

  2010cited by this paper
• The worldwide societal costs of dementia: Estimates for 2009

  2010cited by this paper
• Apolipoprotein E ε4 Prevalence in Alzheimer’s Disease Patients Varies across Global Populations: A Systematic Literature Review and Meta-Analysis

  2010cited by this paper
• O3‐07‐03: A novel multivalent Abeta peptide vaccine with preclinical evidence of a central immune response that generates antisera recognizing a wide range of Abeta peptide species

  2010cited by this paper
• O3‐07‐06: Processes underlying the vascular pathophysiology associated with Aβ immunization in Alzheimer's disease

  2010cited by this paper
• P3‐275: Optimization of the treatment regimen with active Aß immunotherapy CAD106 in alzheimer patients

  2010cited by this paper
• 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

  2010influential reference
• P3‐450: Safety and pharmacokinetics following a single 10‐minute intravenous infusion of the anti‐amyloid mAb ponezumab (PF‐04360365) in patients with mild to moderate Alzheimer's disease

  2010influential reference
• Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid &bgr; After a Single Administration of an Amyloid &bgr; Monoclonal Antibody in Subjects With Alzheimer Disease

  2010influential reference
• Intravenous Immunoglobulins as a Treatment for Alzheimer’s Disease

  2010cited by this paper
• P3‐445: Fitness for the aging brain study II: A multisite randomized controlled trial to determine the clinical benefits of physical activity for patients with mild‐to‐moderate Alzheimer's disease

  2010cited by this paper
• Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease

  2010cited by this paper
• A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease

  2010influential reference
• Murine models of Alzheimer's disease and their use in developing immunotherapies.

  2010cited by this paper
• P4‐118: Safety and Pharmacokinetics Following a Single Infusion of the Anti‐amyloid Monoclonal Antibody Ponezumab (pf‐04360365) in Patients With Mild‐to‐moderate Alzheimer's Disease: Final Results

  2010influential reference
• The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics

  2009cited by this paper
• Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders

  2009influential reference
• Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease

  2009cited by this paper
• A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

  2009cited by this paper
• Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease

  2009cited by this paper
• IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders

  2009cited by this paper
• 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

  2009influential reference
• P1‐275: Measurement of cerebrospinal fluid total tau and phospho‐tau in phase 2 trials of therapies targeting Aβ

  2009cited by this paper
• S2‐02‐05: Biochemical biomarkers as endpoints in clinical trials: Applications in Phase 1, 2 and 3 studies

  2009cited by this paper
• O2‐05‐03: Immunotherapy targeting abnormal protein conformation

  2009cited by this paper
• O4‐04‐01: Citalopram compared to atypical antipsychotics for Alzheimer patients who did not previously benefit from treatment: The catie‐AD study

  2009cited by this paper
• P1‐277: Effects of repeated screening and potential impact on AD prevention trial design: The antioxidant AD prevention (PREADVISE) trial

  2009cited by this paper
• O2‐05‐05: Results of the first‐in‐man study with the active Aβ Immunotherapy CAD106 in Alzheimer patients

  2009cited by this paper
• O4‐04‐02: Identification, characterization, and comparison of amino‐terminally truncated Aβ42 peptides in Alzheimer's disease brain tissue and in plasma from Alzheimer's patients receiving solanezumab immunotherapy treatment

  2009cited by this paper
• Development of AFFITOPE vaccines for Alzheimer's disease (AD) — From concept to clinical testing

  2009cited by this paper
• Progress in the Active Immunotherapeutic Approach to Alzheimer’s Disease: Clinical Investigations into AN1792-Associated Meningoencephalitis

  2008cited by this paper
• S2‐04–06: Safety, tolerability and immunogenicity of the Aβ immunotherapeutic vaccine CAD106 in a first‐in‐man study in Alzheimer patients

  2008cited by this paper
• Neuropsychological correlates of whole brain atrophy in Alzheimer's disease.

  2008cited by this paper
• Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.

  2008cited by this paper
• Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report.

  2007cited by this paper
• Course of cerebral amyloid angiopathy–related inflammation

  2007cited by this paper
• Imaging of amyloid burden and distribution in cerebral amyloid angiopathy

  2007cited by this paper
• Amyloid- (cid:1) Peptide Remnants in AN-1792-Immunized Alzheimer’s Disease Patients A Biochemical Analysis

  2006cited by this paper
• A&bgr; Species Removal After A&bgr;42 Immunization

  2006cited by this paper
• CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

  2006cited by this paper
• Aβ42 immunization in Alzheimer's disease generates Aβ N‐terminal antibodies

  2005cited by this paper
• Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease

  2005cited by this paper
• Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.

  2005cited by this paper
• Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders.

  2005cited by this paper
• Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD

  2005influential reference
• Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

  2005cited by this paper
• Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

  2005influential reference
• CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.

  2005cited by this paper
• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

  2004cited by this paper
• Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease

  2004cited by this paper
• Clinical manifestations of cerebral amyloid angiopathy–related inflammation

  2004cited by this paper
• Passive Amyloid Immunotherapy Clears Amyloid and Transiently Activates Microglia in a Transgenic Mouse Model of Amyloid Deposition

  2004cited by this paper
• Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer’s disease

  2004influential reference
• Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

  2003influential reference
• APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein.

  2003cited by this paper
• Amyloid-β Immunization Effectively Reduces Amyloid Deposition in FcRγ-/- Knock-Out Mice

  2003cited by this paper
• Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice.

  2003cited by this paper
• Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

  2003cited by this paper
• APOEɛ4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of Aβ protein

  2003cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy

  2002cited by this paper
• Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease

  2001cited by this paper
• Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

  2001cited by this paper
• Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

  2001cited by this paper
• Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

  2000cited by this paper
• Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

  2000cited by this paper
• A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

  2000cited by this paper
• Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

  2000cited by this paper
• A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

  2000cited by this paper
• Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

  1999influential reference
• Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide.

  1996cited by this paper
• 1 The GloBAl eCoNomiC impACT oF demeNTiA Alzheimer ’ s diseAse internAtionAl World Alzheimer report 2010 the GlobAl economic impAct of dementiA

  year unknowncited by this paper
• Uber eine eigenartige Erkrankung der Hirnrinde

  year unknowncited by this paper

• Natural products against tau hyperphosphorylation‐induced aggregates: Potential therapies for Alzheimer's disease

  2025cites this paper
• CASP8 intronic expansion identified by poly-glycine-arginine pathology increases Alzheimer’s disease risk

  2025cites this paper
• Herpes simplex virus‐1 infection alters microtubule‐associated protein Tau splicing and promotes Tau pathology in neural models of Alzheimer's disease

  2025cites this paper
• HSV-1 Infection Alters MAPT Splicing and Promotes Tau Pathology in Neural Models of Alzheimer’s Disease

  2024cites this paper
• Exploring Curcumin-Loaded Lipid-Based Nanomedicine as Efficient Targeted Therapy for Alzheimer's Diseases.

  2024cites this paper
• A Molecular Integrative Study on the Inhibitory Effects of WRR and ERW on Amyloid β Peptide (1–42) Polymerization and Cell Toxicity

  2023cites this paper
• A Neuroprotective Action of Quercetin and Apigenin through Inhibiting Aggregation of Aβ and Activation of TRKB Signaling in a Cellular Experiment

  2023cites this paper
• A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro

  2022cites this paper
• Amyloid-β in Alzheimer’s disease – front and centre after all?

  2022cites this paper
• The Role of Lipid Domains and Physical Properties of Membranes in the Development of Age-Related Neurodegenerative Diseases

  2022cites this paper
• Circular RNAs in Alzheimer's Disease: A New Perspective of Diagnostic and Therapeutic Targets.

  2022cites this paper
• Bioactive Compounds and Their Derivatives: An Insight into Prospective Phytotherapeutic Approach against Alzheimer's Disease

  2022cites this paper
• Current Drug Targets in Alzheimer's Associated Memory Impairment: A Comprehensive Review.

  2022cites this paper
• Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer's disease pathology in aged squirrel monkeys.

  2021cites this paper
• Targeting the TLR4/NF-κB pathway in β-amyloid-stimulated microglial cells: a possible mechanism that oxysophoridine exerts anti-oxidative and anti-inflammatory effects in an in vitro model of Alzheimer's disease.

  2021cites this paper
• RRY Inhibits Amyloid-β1–42 Peptide Aggregation and Neurotoxicity

  2021cites this paper
• PLGA-PEG Nanoparticles Facilitate In Vivo Anti-Alzheimer's Effects of Fucoxanthin, a Marine Carotenoid Derived from Edible Brown Algae.

  2021cites this paper
• Calcium Dyshomeostasis in Alzheimer’s Disease Pathogenesis

  2021cites this paper
• Yeast-Based Aβ1-15 Vaccine Elicits Strong Immunogenicity and Attenuates Neuropathology and Cognitive Deficits in Alzheimer’s Disease Transgenic Mice

  2020cites this paper
• Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials

  2020cites this paper
• Effects of Coriandrum sativum Seed Extract on Aging-Induced Memory Impairment in Samp8 Mice

  2020cites this paper
• Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology.

  2020cites this paper
• Simulations on the dual effects of flavonoids as suppressors of Aβ42 fibrillogenesis and destabilizers of mature fibrils

  2020cites this paper
• From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer’s Disease

  2020cites this paper
• Stimulation Effects and Mechanisms of Different Adjuvants on a Norovirus P Particle-Based Active Amyloid-β Vaccine

  2020cites this paper
• Effect of CTerm of human albumin on the aggregation propensity of Aβ1-42 peptide: a potential of mean force study

  2020cites this paper
• Therapeutic vaccines for amyotrophic lateral sclerosis directed against disease specific epitopes of superoxide dismutase 1.

  2019cites this paper
• Active immunization with norovirus P particle-based amyloid-β chimeric protein vaccine induces high titers of anti-Aβ antibodies in mice

  2019cites this paper
• Norepinephrine Inhibits Alzheimer's Amyloid-β Peptide Aggregation and Destabilizes Amyloid-β Protofibrils: A Molecular Dynamics Simulation Study.

  2019cites this paper
• Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings

  2019cites this paper
• Farrerol attenuates β-amyloid-induced oxidative stress and inflammation through Nrf2/Keap1 pathway in a microglia cell line.

  2019cites this paper
• Tau-targeting therapies for Alzheimer disease

  2018cites this paper
• Memory Loss and the Onset of Alzheimer’s Disease Could Be Under the Control of Extracellular Heat Shock Proteins

  2018cites this paper
• Prévention du phénomène de nucléation et de la propagation des tauopathies par immunothérapie passive utilisant un anticorps ciblant une région centrale de la protéine tau

  2018cites this paper
• Beta Amyloid Peptides : Extracellular and Intracellular

  2018cites this paper
• Emerging Immunotherapies for Parkinson Disease

  2018cites this paper
• Modulation of Alzheimer's amyloid β peptide oligomerization and toxicity by extracellular Hsp70

  2018cites this paper
• Topological Biomarker of Alzheimer’s Disease

  2018cites this paper
• The Mechanisms of Action of Curcumin in Alzheimer’s Disease

  2017cites this paper
• Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease.

  2017cites this paper
• Destination Brain: the Past, Present, and Future of Therapeutic Gene Delivery

  2017cites this paper
• Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency

  2017cites this paper
• Alzheimer's Disease: Dawn of a New Era?

  2017cites this paper
• Norovirus P particle-based active Aβ immunotherapy elicits sufficient immunogenicity and improves cognitive capacity in a mouse model of Alzheimer’s disease

  2017cites this paper
• Magnetic Fluorescent Nanoparticles Binding to Amyloid-Beta Peptide: Silica-Coated, Thioflavin-T Functionalized Iron Oxide

  2017cites this paper
• Potential of GPCRs to modulate MAPK and mTOR pathways in Alzheimer's disease.

  2017cites this paper
• Screening and evaluation of natural compounds for therapeutic application in Alzheimer's disease

  2016cites this paper
• Active Immunization Against the Amyloid-β Peptide

  2016cites this paper
• Prion diseases: immunotargets and therapy

  2016influential citation
• Immunotherapies in Alzheimer’s disease: Too much, too little, too late or off-target?

  2016cites this paper
• Alzheimer’s disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules

  2016cites this paper
• Longitudinal Characterization of [18F]-FDG and [18F]-AV45 Uptake in the Double Transgenic TASTPM Mouse Model

  2016cites this paper
• Beta Amyloid Peptides: Extracellular and Intracellular Mechanisms of Clearance in Alzheimer’s Disease

  2016cites this paper
• Human cystatin C monomer, dimer, oligomer, and amyloid structures are related to health and disease

  2016cites this paper
• A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease

  2015influential citation
• From Dark to Bright to Gray Sides of Memory: In Search of its Molecular Basis & Alzheimer’s Disease

  2015cites this paper
• Natural products from marine organisms with neuroprotective activity in the experimental models of Alzheimer’s disease, Parkinson’s disease and ischemic brain stroke: their molecular targets and action mechanisms

  2015cites this paper
• eview xploring the Alzheimer amyloid-peptide conformational nsemble : A review of molecular dynamics approaches

  2015cites this paper
• Aging Mechanisms

  2015cites this paper
• Immunotherapeutic Approaches Against Amyloid-β in Drug Discovery for Alzheimer’s Disease

  2015cites this paper
• Hemodynamic changes in Alzheimer's disease: A leading role behind the courtain? Commentary on “CSF Aβ1‐42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease” by Lista et al.

  2015cites this paper
• Engineering of Affibody molecules targeting the Alzheimer’s-related amyloid β peptide

  2015cites this paper
• Structural Characterization of Interactions between the Alzheimer’s Disease Amyloid-Beta Peptide and Small Molecules and Peptide Inhibitors

  2015cites this paper
• COB231 targets amyloid plaques in post‐mortem human brain tissue and in an Alzheimer mouse model

  2015cites this paper
• A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-β-amyloid antibody responses in mice with pre-existing virus specific memory.

  2014cites this paper
• Amyloid vaccine for Alzheimer’s disease- Is it feasible?

  2014cites this paper
• Role of complement systems in IVIG mediated attenuation of cognitive deterioration in Alzheimer's disease.

  2014cites this paper
• Active immunotherapy options for Alzheimer's

  2014cites this paper
• A Fab fragment directed against the neural cell adhesion molecule L1 enhances functional recovery after injury of the adult mouse spinal cord.

  2014cites this paper
• The MultiTEP platform–based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates

  2014cites this paper
• Biotechnologically engineered protein binders for applications in amyloid diseases.

  2014cites this paper
• Lymphocytes and autoimmunity after spinal cord injury.

  2014cites this paper
• The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice

  2014cites this paper
• Immunogenicity of DNA- and recombinant protein-based Alzheimer Disease epitope vaccines

  2014cites this paper
• Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics

  2014cites this paper
• Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease

  2014cites this paper
• Innate Immune System and Inflammation in Alzheimer's Disease: From Pathogenesis to Treatment

  2014cites this paper
• Natural products from marine organisms with neuroprotective activity in the experimental models of Alzheimer’s disease, Parkinson’s disease and ischemic brain stroke: their molecular targets and action mechanisms

  2014cites this paper
• Active immunotherapy options for Alzheimer’s disease

  2014cites this paper
• A Generic Method for Design of Oligomer-Specific Antibodies

  2014cites this paper
• Epitope‐based DNA vaccine for Alzheimer's disease: Translational study in macaques

  2014cites this paper
• Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human α-synuclein: feasibility study.

  2014cites this paper
• Biomarker utility in Alzheimer's disease clinical trials

  2013cites this paper
• A synthetic peptide corresponding to a region of the human pericentriolar material 1 (PCM‐1) protein binds β‐amyloid (Aβ1‐42) oligomers

  2013influential citation
• Rare Types of Amyloidosis and their Pathogenesis: Targets for Innovative Therapy

  2013cites this paper
• Evidence for Prion-Like Mechanisms in Several Neurodegenerative Diseases: Potential Implications for Immunotherapy

  2013cites this paper
• IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway.

  2013cites this paper
• Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

  2013cites this paper
• Molecular and morphological analyses of basal forebrain cholinergic neurons in mouse models of aging and Alzheimer's disease

  2013cites this paper
• Neuroinflammation and Neuronal Loss Precede Aβ Plaque Deposition in the hAPP-J20 Mouse Model of Alzheimer’s Disease

  2013cites this paper
• Antibody-conjugated, dual-modal, near-infrared fluorescent iron oxide nanoparticles for antiamyloidgenic activity and specific detection of amyloid-β fibrils

  2013cites this paper
• Amelioration Of Amyloid Burden In Advanced Human And Mouse Alzheimer's Disease Brains By Oral Delivery Of Myelin Basic Protein Bioencapsulated In Plant Cells

  2012cites this paper
• Current status of vaccination therapies in Alzheimer's disease

  2012cites this paper